XIAP and cancer: Several cancers have acquired resistance to interleukin-mediated apoptosis primarily because of reduced TRAIL-R1/-R2 expression, the over-expression of anti-apoptotic proteins like XIAP and c-FLIP, or elevated TRAIL decoy receptors TRAIL-R3/R4 [47].